- Conditions
- Graft Rejection, Kidney Transplantation, Renal Transplantation
- Interventions
- Belatacept, Cyclosporine, Mycophenolate mofetil (MMF), Corticosteroids
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2012
- U.S. locations
- 12
- States / cities
- San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 204
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Rheumatoid Arthritis
- Interventions
- Abatacept
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 55 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Abatacept, placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 20
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Huntington Beach, California + 17 more
- Conditions
- COVID-19
- Interventions
- abatacept infusion, Placebo group
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 82
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Davis, California + 58 more
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Abatacept
- Drug
- Lead sponsor
- Arthritis Northwest PLLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Spokane, Washington
- Conditions
- Kidney Transplantation
- Interventions
- Belatacept
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Rheumatoid Arthritis
- Interventions
- Abatacept, placebo, methotrexate
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,052 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 19
- States / cities
- Huntsville, Alabama • Huntington Beach, California • Colorado Springs, Colorado + 15 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Abatacept, Methotrexate, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2009
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 45 more
- Conditions
- AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
- Interventions
- Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
- Drug · Procedure · Other
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- 18 Years to 66 Years
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
- Conditions
- Lung Transplant Rejection, Antibody-mediated Rejection
- Interventions
- Belatacept, Tacrolimus, ATG, Mycophenolate Mofetil, Methylprednisolone, Prednisone
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • Houston, Texas
- Conditions
- Primary Biliary Cirrhosis
- Interventions
- abatacept
- Biological
- Lead sponsor
- Christopher Bowlus, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Kidney Transplant Recipient
- Interventions
- Abatacept 125Mg/Ml Syringe
- Drug
- Lead sponsor
- Idelberto Badell
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Rheumatoid Arthritis
- Interventions
- Abatacept
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Disorder Related to Renal Transplantation
- Interventions
- Thymoglobulin, Belatacept, Sirolimus, Tacrolimus, Mycophenolate Mofetil (MMF)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 11
- States / cities
- San Francisco, California • Denver, Colorado • Augusta, Georgia + 7 more
- Conditions
- Kidney Transplant Rejection
- Interventions
- Carfilzomib, Belatacept
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 7 more
- Conditions
- Graft Vs Host Disease
- Interventions
- Placebo, Abatacept
- Drug
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 15
- States / cities
- Duarte, California • Tampa, Florida • Atlanta, Georgia + 8 more
- Conditions
- Transplant; Failure, Kidney, EBV
- Interventions
- belatacept, Tacrolimus, MPA
- Drug
- Lead sponsor
- Lorenzo Gallon
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Hypertension
- Interventions
- Abatacept, Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Immunosuppression
- Interventions
- Belatacept, Hand transplant
- Drug · Procedure
- Lead sponsor
- Linda Cendales
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Rheumatoid Arthritis
- Interventions
- Abatacept or Placebo (both as IV & SC solution), Abatacept
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 5
- States / cities
- Orlando, Florida • Atlanta, Georgia • New Orleans, Louisiana + 2 more
- Conditions
- CTLA4 Haploinsufficency, Chronic Cytopenia
- Interventions
- abatacept, Placebo
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 8 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Sickle Cell Disease
- Interventions
- Cyclophosphamide 50mg, Abatacept, Alemtuzumab, Hydroxyurea, Thiotepa, Filgrastim, Sirolimus, Azathioprine, TBI, Hematopoietic Progenitor Cell Infusion
- Drug · Radiation · Procedure
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 22 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2035
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Urticaria
- Interventions
- abatacept (Orencia ®)
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Psoriasis
- Interventions
- Secukinumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 17,743 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey